VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

Jianjun Gao; John F. Ward; Curtis A. Pettaway; Lewis Z. Shi; Sumit K. Subudhi; Luis M. Vence; Hao Zhao; Jianfeng Chen; Hong Chen; Eleni Efstathiou; Patricia Troncoso; James P. Allison; Christopher J. Logothetis; Ignacio I. Wistuba; Manuel A. Sepulveda; Jingjing Sun; Jennifer Wargo; Jorge Blando; Padmanee Sharma

doi:10.1038/nm.4308

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

Jianjun Gao, John F. Ward, Curtis A. Pettaway, Lewis Z. Shi, Sumit K. Subudhi, Luis M. Vence, Hao Zhao, Jianfeng Chen, Hong Chen, Eleni Efstathiou, Patricia Troncoso, James P. Allison, Christopher J. Logothetis, Ignacio I. Wistuba, Manuel A. Sepulveda, Jingjing Sun, Jennifer Wargo, Jorge Blando, Padmanee Sharma

Research output: Contribution to journal › Article › peer-review

491 Scopus citations

Abstract

To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.

Original language	English (US)
Pages (from-to)	551-555
Number of pages	5
Journal	Nature medicine
Volume	23
Issue number	5
DOIs	https://doi.org/10.1038/nm.4308
State	Published - May 1 2017

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

MD Anderson CCSG core facilities

Clinical and Translational Research Center
Flow Cytometry and Cellular Imaging Facility
Research Animal Support Facility
Tissue Biospecimen and Pathology Resource
Clinical Trials Office

Access to Document

10.1038/nm.4308

Cite this

Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., Troncoso, P., Allison, J. P., Logothetis, C. J., Wistuba, I. I., Sepulveda, M. A., Sun, J., Wargo, J., Blando, J., & Sharma, P. (2017). VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature medicine, 23(5), 551-555. https://doi.org/10.1038/nm.4308

Gao, J , Ward, JF , Pettaway, CA, Shi, LZ, Subudhi, SK, Vence, LM, Zhao, H, Chen, J , Chen, H, Efstathiou, E, Troncoso, P , Allison, JP , Logothetis, CJ , Wistuba, II, Sepulveda, MA, Sun, J , Wargo, J, Blando, J & Sharma, P 2017, 'VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer', Nature medicine, vol. 23, no. 5, pp. 551-555. https://doi.org/10.1038/nm.4308

@article{de5814e2633149a9af32c0e880c06316,

title = "VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer",

abstract = "To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.",

author = "Jianjun Gao and Ward, {John F.} and Pettaway, {Curtis A.} and Shi, {Lewis Z.} and Subudhi, {Sumit K.} and Vence, {Luis M.} and Hao Zhao and Jianfeng Chen and Hong Chen and Eleni Efstathiou and Patricia Troncoso and Allison, {James P.} and Logothetis, {Christopher J.} and Wistuba, {Ignacio I.} and Sepulveda, {Manuel A.} and Jingjing Sun and Jennifer Wargo and Jorge Blando and Padmanee Sharma",

year = "2017",

month = may,

day = "1",

doi = "10.1038/nm.4308",

language = "English (US)",

volume = "23",

pages = "551--555",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "5",

}

TY - JOUR

T1 - VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

AU - Gao, Jianjun

AU - Ward, John F.

AU - Pettaway, Curtis A.

AU - Shi, Lewis Z.

AU - Subudhi, Sumit K.

AU - Vence, Luis M.

AU - Zhao, Hao

AU - Chen, Jianfeng

AU - Chen, Hong

AU - Efstathiou, Eleni

AU - Troncoso, Patricia

AU - Allison, James P.

AU - Logothetis, Christopher J.

AU - Wistuba, Ignacio I.

AU - Sepulveda, Manuel A.

AU - Sun, Jingjing

AU - Wargo, Jennifer

AU - Blando, Jorge

AU - Sharma, Padmanee

PY - 2017/5/1

Y1 - 2017/5/1

N2 - To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.

AB - To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.

UR - http://www.scopus.com/inward/record.url?scp=85016090030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016090030&partnerID=8YFLogxK

U2 - 10.1038/nm.4308

DO - 10.1038/nm.4308

M3 - Article

C2 - 28346412

AN - SCOPUS:85016090030

SN - 1078-8956

VL - 23

SP - 551

EP - 555

JO - Nature medicine

JF - Nature medicine

IS - 5

ER -

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this